More than half of patients with microsatellite-stable metastatic colorectal cancer without active liver metastases survived at least 18 months with botensilimab plus balstilimab.
|Articles|March 1, 1995
Oncology NEWS International
- Oncology NEWS International Vol 4 No 3
- Volume 4
- Issue 3
Medicare Physician Fees Set for 1995
WASHINGTON--Health and Human Services Secretary Donna Shalala has announced that Medicare physician fees will be increased in 1995--by 7.9% for primary services, 12.2% for surgical services, and 5.2% for other services. Payments for
Advertisement
WASHINGTON--Health and Human Services Secretary Donna Shalalahas announced that Medicare physician fees will be increased in1995--by 7.9% for primary services, 12.2% for surgical services,and 5.2% for other services. Payments for physician services incalendar year 1995 are expected to be $2.2 billion higher thanin 1994
Articles in this issue
over 31 years ago
Selecting a Support Group for Patients With Prostate Carcinomaover 31 years ago
Antman Provides Outlook on Use of High-Dose Chemoover 31 years ago
Radiofrequency Ablation of Brain Tumors New Optionover 31 years ago
Oncologist Enthusiastic About Capitated Planover 31 years ago
Varmins Chooses New Director for NIH Office of Alternative Medicineover 31 years ago
'Visible Man' Hits the Internet, Radiologists Get the First Lookover 31 years ago
Ultrafast Full-Body MRI Eases Procedure in Claustrophobics, KidsAdvertisement
Related to this article
Investigators will present detailed findings from a phase 2 study assessing a tambiciclib-based regimen in patients with relapsed/refractory AML at ASH 2026.
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists perform brachytherapy, and one setting where he considers it the better option.
Chinmay Jani, MD, discusses ASCO 2026 data on lung cancer trends in younger adults and why this group has been overlooked.
Data from the OrigAMI-4 trial support the accelerated approval of amivantamab and hyaluronidase-lpuj for this HNSCC population.
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.
Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
FDA Sets PDUFA Date for Rivoceranib/Camrelizumab Resubmission After Third CRL in Unresectable HCC
3
Sacituzumab Govitecan Efficacy, Safety Debated in First-Line Metastatic TNBC
4
Air Pollution Emerges as Second Leading Risk Factor for Lung Cancer Deaths
5